{"id":87799,"date":"2023-07-28T05:37:12","date_gmt":"2023-07-28T05:37:12","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=111625"},"modified":"2023-07-28T05:37:12","modified_gmt":"2023-07-28T05:37:12","slug":"nyxoah-to-participate-in-the-43rd-canaccord-genuity-growth-conference","status":"publish","type":"post","link":"https:\/\/jordannewsgazette.com\/nyxoah-to-participate-in-the-43rd-canaccord-genuity-growth-conference\/","title":{"rendered":"Nyxoah to Participate in the 43rd Canaccord Genuity Growth Conference"},"content":{"rendered":"
\n

Nyxoah to Participate in the<\/strong> 43rd<\/strong> Canaccord Genuity Growth<\/strong> Conference<\/strong><\/p>\n

Mont-Saint-Guibert, Belgium \u2013 <\/strong>July <\/strong>27<\/strong>, 2023, 10:30pm CET \/ 4:30pm ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)<\/strong> (\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Canaccord Genuity 43rd<\/sup> Growth Conference, which takes place August 7 \u2013 10, 2023 in Boston, Massachusetts.<\/p>\n

Olivier Taelman, Nyxoah\u2019s Chief Executive Officer, will deliver a corporate update on Wednesday, August\u00a09, 2023, at 9:30am EST. A webcast<\/a> of the presentation will be available on the Events section<\/a> of Nyxoah\u2019s Investor Relations website. The Company will also be available for 1×1 meetings with institutional investors attending the event.<\/p>\n

Nyxoah\u2019s Investor Presentation can be accessed on the Shareholder Information<\/a> section of the Company\u2019s Investor Relations page.<\/p>\n

About Nyxoah<\/strong>
\nNyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah\u2019s lead solution is the Genio\u00ae system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world\u2019s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.<\/p>\n

Following the successful completion of the BLAST OSA study, the Genio\u00ae system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors\u2019 therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.<\/p>\n

For more information, please visit http:\/\/www.nyxoah.com\/<\/a>.<\/p>\n

Caution <\/strong>\u2013 CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.<\/p>\n

Contact:<\/strong>
\nNyxoah<\/strong>
\nDavid DeMartino, Chief Strategy Officer
\ndavid.demartino@nyxoah.com <\/a>
\n+1 310 310 1313<\/p>\n

Attachment<\/strong><\/p>\n